Last reviewed · How we verify
Carafate
Carafate is a Aluminum Complex [EPC] Small molecule drug developed by Forest Labs Inc. It is currently FDA-approved (first approved 1981) for Duodenal ulcer disease, Maintenance of Healing Duodenal Ulcer.
At a glance
| Generic name | Carafate |
|---|---|
| Sponsor | Forest Labs Inc |
| Drug class | Aluminum Complex [EPC] |
| Target | Pepsin A-5 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Duodenal ulcer disease
- Maintenance of Healing Duodenal Ulcer
Common side effects
- Constipation
Drug interactions
- dolutegravir
- gemifloxacin
- moxifloxacin
- zalcitabine
Key clinical trials
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2,PHASE3)
- Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation (PHASE2)
- Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled Trial (PHASE4)
- Precise Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Bleeding: A Randomized Controlled Trial (NA)
- Prevention of Post-sphincterotomy Bleeding (NA)
- Endoscopically-delivered Purastat to Treat Bleeding Caused by Radiation Proctopathy (NA)
- Short-Term Outcome of Medical Vs. Surgical Management Of Chronic Anal Fissure (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carafate CI brief — competitive landscape report
- Carafate updates RSS · CI watch RSS
- Forest Labs Inc portfolio CI
Frequently asked questions about Carafate
What is Carafate?
Carafate is a Aluminum Complex [EPC] drug developed by Forest Labs Inc, indicated for Duodenal ulcer disease, Maintenance of Healing Duodenal Ulcer.
What is Carafate used for?
Carafate is indicated for Duodenal ulcer disease, Maintenance of Healing Duodenal Ulcer.
Who makes Carafate?
Carafate is developed and marketed by Forest Labs Inc (see full Forest Labs Inc pipeline at /company/forest-labs-inc).
What drug class is Carafate in?
Carafate belongs to the Aluminum Complex [EPC] class. See all Aluminum Complex [EPC] drugs at /class/aluminum-complex-epc.
When was Carafate approved?
Carafate was first approved on 1981.
What development phase is Carafate in?
Carafate is FDA-approved (marketed).
What are the side effects of Carafate?
Common side effects of Carafate include Constipation.
What does Carafate target?
Carafate targets Pepsin A-5 and is a Aluminum Complex [EPC].
Related
- Drug class: All Aluminum Complex [EPC] drugs
- Target: All drugs targeting Pepsin A-5
- Manufacturer: Forest Labs Inc — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Duodenal ulcer disease
- Indication: Drugs for Maintenance of Healing Duodenal Ulcer
- Compare: Carafate vs similar drugs
- Pricing: Carafate cost, discount & access